Effects of Different Doses of Oral Iron on Hepcidin and Treatment Response in Iron Deficiency Anemia

Basit Öğe Kaydı
dc.authoridBEYLER, Ozlem/0000-0002-2032-8877
dc.contributor.authorBeyler, Ozlem
dc.contributor.authorDemir, Cengiz
dc.contributor.authorDemircan, Vehbi
dc.contributor.authorKacmaz, Murat
dc.date.accessioned2025-02-22T14:09:04Z
dc.date.available2025-02-22T14:09:04Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroductionIron deficiency anemia (IDA) is a common health problem. The hepcidin hormone is the main regulator of systemic iron balance. The body responds to IDA by decreasing hepcidin. This study investigated how different iron supplementation regimens affect hepcidin levels in women with IDA. 87 female participants aged 18-45 years with hemoglobin < 10 g/dL and serum ferritin < 20 ng/ml were assigned to receive iron therapy every other day, once daily, or twice daily. Hemogram, serum iron, serum iron binding capacity, ferritin, hepcidin, and C-reactive protein values were measured at baseline and on the 15th and 90th days of treatment in all groups. On the seventh day, no significant difference was found between the once-daily and twice-daily groups (p = 0.42) in reticulocyte counts. By the 15th day, hemoglobin and MCV levels showed significant improvement in the twice-daily group compared to the other groups (p < 0.01). At the third month, ferritin levels were significantly higher in the twice-daily group compared to the every-other-day and once-daily groups (p = 0.03). No significant differences were observed in hepcidin levels at three months across all groups. The study concludes that twice-daily iron supplementation results in the most significant hematological improvements but with increased gastrointestinal side effects. These findings underscore the importance of tailoring iron dosing schedules to individual patient needs. In cases where rapid haemoglobin response is required, twice-daily dosing may provide superior results. Conversely, once-daily dosing may be preferred if tolerable anemia can be maintained. Every other day dosing, although associated with fewer side effects and better tolerability, may not provide adequate support for erythropoiesis.en_US
dc.identifier.doi10.1007/s12288-024-01844-5
dc.identifier.issn0971-4502
dc.identifier.issn0974-0449
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1007/s12288-024-01844-5
dc.identifier.urihttps://hdl.handle.net/11468/29778
dc.identifier.wosWOS:001303890800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofIndian Journal of Hematology and Blood Transfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectHepcidinen_US
dc.subjectAnemiaen_US
dc.subjectIron deficiencyen_US
dc.subjectIronen_US
dc.titleEffects of Different Doses of Oral Iron on Hepcidin and Treatment Response in Iron Deficiency Anemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu